| Document |
Document Title |
|
WO/2020/234828A1 |
A method of inhibiting GAPDH with certain oxathiazin-like compounds and/or related compounds.
|
|
WO/2020/094542A1 |
The invention relates to 5,6-diphenyl-5,6-dihydro- dibenz[c,e][1,2 ]azaphosphorin and 6-phenyl-6H-dibenzo[c,e] [1,2]thiazin-5,5 dioxide derivatives and similar compounds of the formula (1) as organic electroluminescent materials for use ...
|
|
WO/2020/046132A1 |
The present invention relates to therapeutic methods for the management of a patient's lysosomal storage disease by enzyme replacement therapy. The methods involve the use of combinations of, and kits containing: a) an exogenous lysosoma...
|
|
WO/2020/016434A1 |
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection an...
|
|
WO/2019/213987A1 |
Disclosed are a monophosphine ligand based on a tetramethyl spirobiindane skeleton and an intermediate thereof, and a preparation method therefor and the use thereof. The monophosphine ligand is a compound having the structure represente...
|
|
WO/2019/141369A1 |
The present invention generally relates to a process for the preparation of a product, the prod- uct being 6-methyl-3,4-dihydro1,2,3-oxathiazin-4-one 2,2-dioxide or a derivative thereof. The present invention also relates to the use of s...
|
|
WO/2019/114999A1 |
In general, the invention relates to a process for the preparation of acesulfame or a derivative thereof. More specifically, the invention relates to a process, to a product obtainable by the process and the use of a specified velocity o...
|
|
WO/2019/104199A1 |
The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through ...
|
|
WO/2019/101132A1 |
Disclosed in the present invention are a fluorosulfonyl-containing compound, an intermediate thereof, a preparation method therefor and use thereof. The fluorosulfonyl-containing compound disclosed in the present invention comprises a ca...
|
|
WO/2019/104201A1 |
The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through ...
|
|
WO/2019/095599A1 |
A photocrosslinked hydrogel material. The material is prepared by: dissolving a component A, a photosensitive polymer derivative, in a biocompatible medium to obtain a photosensitive polymer solution A; dissolving a component B, a photoi...
|
|
WO/2019/095600A1 |
Provided are preparation, raw materials, a product, and an application of a photocoupled synergistic crosslinked hydrogel material. The material is prepared by: dissolving a component A, a polymer derivative modified by an o-nitrobenzyl ...
|
|
WO/2019/094732A1 |
The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating diseases associated with the binding of CREB to CREB-binding protein (CBP) and...
|
|
WO/2019/053617A1 |
The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to FormµLa (I): wherein R, R1,P, X, Y, and Z are as defined herein; or a pharmaceutically acceptable salt ...
|
|
WO/2018/237145A1 |
The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for the treatment and/or prevention of neurodegenerative disease, mitchonodrial disease, fibrosis, and/or cardiomyopathy.
|
|
WO/2018/107112A1 |
Embodiments are directed to compounds of the formulae (I), (Ia), (Ib), (II), (IIa) (III), (IV), (V), and (VI); methods for treating cancer with one or more compounds of the formulae (I), (Ia), (Ib), (II), (IIa); (III), (IV), (V), and (VI...
|
|
WO/2018/057389A1 |
A process for producing acesulfame potassium, the process comprising the steps of providing a cyclizing agent composition comprising a cyclizing agent and a solvent and having an initial temperature, cooling the cyclizing agent compositi...
|
|
WO/2018/057387A1 |
Compositions and processes for producing high purity acesulfame potassium are described. One process comprises the steps of forming a cyclic sulfur trioxide adduct; hydrolyzing the cyclic sulfur trioxide adduct to form an acesulfame-H co...
|
|
WO/2018/057388A1 |
Compositions and processes for producing high purity acesulfame potassium are described. One process comprises the steps of providing a crude acesulfame potassium composition comprising acesulfame potassium and acetoacetamide, concentrat...
|
|
WO/2018/057386A1 |
Improved processes for producing high purity acesulfame potassium. In one embodiment, the process comprises the steps of contacting a solvent, e.g., dichloromethane, and a cyclizing agent, e.g., sulfur trioxide, to form a cyclizing agent...
|
|
WO/2018/051255A1 |
The present invention relates to cyclic substituted 1,3,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signaling pathway and/or for treatment of disorders by inhibiting an...
|
|
WO/2018/051254A1 |
The present invention relates to cyclic substituted-1,2,4-oxadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signalling pathway and/or for treatment of disorders by inhibiting an immunosuppress...
|
|
WO/2018/047143A1 |
The present invention relates to VISTA signaling pathway inhibitory compounds of formula (I) which are useful as immune modulators for the treatment of various disease conditions including various types of cancer. The invention also enco...
|
|
WO/2017/175177A1 |
Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes for efficient and safe manufacture of compounds useful for maki...
|
|
WO/2017/024229A8 |
A process for the stereoselective synthesis of chiral 3-heterocyclyl-1,2-dihydroxy cyclohexanes is disclosed. The process involves reacting a tricyclic nitrogenous heterocycle with an allyl carbonate in the presence of a chiral palladium...
|
|
WO/2017/044571A1 |
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus : The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP...
|
|
WO/2017/036404A1 |
Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine ...
|
|
WO/2017/024229A1 |
A process for the stereoselective synthesis of chiral 3-heterocyclyl-1,2-dihydroxy cyclohexanes is disclosed. The process involves reacting a tricyclic nitrogenous heterocycle with an allyl carbonate in the presence of a chiral palladium...
|
|
WO/2017/001655A1 |
Inhibitors of HBV replication of Formula (I-A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R1 to R8 have the meaning as defined herein. The present invention also relates to pr...
|
|
WO/2016/098054A9 |
Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infectio...
|
|
WO/2016/197398A1 |
Disclosed are a sulfonic acid inner salt compound of amidine and a preparation method therefor. The product of a sulfonic acid inner salt of amidine is obtained and synthesized by adopting an o-aminobenzenesulfonyl chloride compound and ...
|
|
WO/2016/116525A1 |
The invention relates to organic molecules, in particular for use in optoelectronic components, such as OLEDs. According to the invention, the organic molecule has a structure of formula 1. In formula 1, n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9...
|
|
WO/2016/098054A1 |
Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infectio...
|
|
WO/2016/055802A1 |
The present invention relates to tetrazole compounds which are of use in the field of agriculture, as fungicides.
|
|
WO/2016/030790A1 |
Oxime sulfonate compounds of the formula (I), wherein R 1 is O(CO)R 4, COOR 5 or CONR 6R 7; n is 1 or 2; R 2 for example is C 1-C 8alkyl, C 3-C 6cycloalkyl or benzyl; R 3 is for example C 1-C 8alkyl, C 3-C 6cycloalkyl, C 1-C 8haloalkyl, ...
|
|
WO/2015/143652A8 |
The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula(I) which are tropomyosin-related kinase(Trk)family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, ...
|
|
WO/2015/143652A1 |
The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula(I) which are tropomyosin-related kinase(Trk)family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, ...
|
|
WO/2015/123365A1 |
The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for the treatment and/or prevention of neurodegenerative disease and/or mitchonodrial disease including Parkinson's disease and Leig...
|
|
WO/2015/110262A1 |
The present invention relates to compounds according to general formula (I) which are analogues of epoxymetabolites produced by cytochrome P450 (CYP) enzymes from omega-3 (n-3) polyunsaturated fatty acids (PUFAs). The present invention f...
|
|
WO/2014/173928A1 |
The present invention is directed to a simple and economical process for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine via novel intermediates and a highly selective asymmetric synthesis leading to enantiopur...
|
|
WO/2014/079935A9 |
The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, G1, n, A1, A2, A3, and A4 are as defined in the claims. The invention also relates to processes and intermediates for preparing these compounds, to insectici...
|
|
WO/2014/079935A1 |
The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, G1, n, A1, A2, A3, and A4 are as defined in the claims. The invention also relates to processes and intermediates for preparing these compounds, to insectici...
|
|
WO/2012/125926A3 |
The present invention relates to novel Tetracyclic Xanthene Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, Y1, Y2, Z, Ra, Rb, R1a, R1b and R2 are as defined herein. The present invention also relates...
|
|
WO/2014/049107A1 |
The present invention concerns compounds of general formula (I): (I) in which Y and Z are chosen from CH and N; T is chosen from CO or SO2; n is 1 to 3; R1 represents a group chosen, for example, from C1-C3 alkyl chains unsubstituted or ...
|
|
WO/2014/003124A1 |
The compound represented by formula (1) or a salt thereof has a collagen production-inhibiting effect, and is thus useful for use in the prevention, treatment, or the like of diseases associated with overproduction of collagen such as pu...
|
|
WO/2013/190355A1 |
New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents.
|
|
WO/2013/182651A1 |
In one embodiment, the invention relates to processes for producing acesulfame potassium. In one embodiment, the process comprises the step of reacting a first reaction mixture to form an amidosulfamic acid salt such as a trialkyl ammoni...
|
|
WO/2013/139697A1 |
The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I ar...
|
|
WO/2013/119564A1 |
It has been determined that co-administration of a rifamycin and a switch-region inhibitor 1) results in synergistic antibacterial effects, enabling efficacy at low, subtoxic doses, and/or 2) results in a low spontaneous resistance frequ...
|
|
WO/2013/096152A1 |
In one embodiment, the invention is to a process for purifying a by-product stream. The process comprises the step of providing a by-product stream comprising an ammonium salt, dimerized amide, and optionally water. The process further c...
|
